On Friday, Verve Therapeutics Inc (NASDAQ: VERV) was 8.12% up from the session before settling in for the closing price of $5.73. A 52-week range for VERV has been $2.86 – $9.31.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
When this article was written, the company’s average yearly earnings per share was at -0.95%. With a float of $65.76 million, this company’s outstanding shares have now reached $88.80 million.
Let’s determine the extent of company efficiency that accounts for 274 employees. In terms of profitability, gross margin is 36.09%, operating margin of -349.68%, and the pretax margin is -303.09%.
Verve Therapeutics Inc (VERV) Insider Activity
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Verve Therapeutics Inc stocks. The insider ownership of Verve Therapeutics Inc is 26.23%, while institutional ownership is 74.01%. The most recent insider transaction that took place on Apr 02 ’25, was worth 40,761. In this transaction Chief Executive Officer of this company sold 9,822 shares at a rate of $4.15, taking the stock ownership to the 346,686 shares. Before that another transaction happened on Apr 02 ’25, when Company’s Chief Administrative Officer sold 2,777 for $4.15, making the entire transaction worth $11,525. This insider now owns 17,420 shares in total.
Verve Therapeutics Inc (VERV) Earnings and Forecasts
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.68 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -0.95% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 0.40% during the next five years compared to -42.43% drop over the previous five years of trading.
Verve Therapeutics Inc (NASDAQ: VERV) Trading Performance Indicators
You can see what Verve Therapeutics Inc (VERV) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 9.84. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 9.26.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.11, a number that is poised to hit -0.67 in the next quarter and is forecasted to reach -2.69 in one year’s time.
Technical Analysis of Verve Therapeutics Inc (VERV)
Looking closely at Verve Therapeutics Inc (NASDAQ: VERV), its last 5-days average volume was 4.18 million, which is a jump from its year-to-date volume of 2.64 million. As of the previous 9 days, the stock’s Stochastic %D was 85.65%. Additionally, its Average True Range was 0.53.
During the past 100 days, Verve Therapeutics Inc’s (VERV) raw stochastic average was set at 51.75%, which indicates a significant decrease from 85.69% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 86.94% in the past 14 days, which was lower than the 108.10% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $4.60, while its 200-day Moving Average is $5.68. However, in the short run, Verve Therapeutics Inc’s stock first resistance to watch stands at $6.59. Second resistance stands at $6.99. The third major resistance level sits at $7.40. If the price goes on to break the first support level at $5.78, it is likely to go to the next support level at $5.37. Should the price break the second support level, the third support level stands at $4.98.
Verve Therapeutics Inc (NASDAQ: VERV) Key Stats
There are 89,143K outstanding shares of the company, which has a market capitalization of 552.24 million. As of now, sales total 32,330 K while income totals -198,710 K. Its latest quarter income was 32,980 K while its last quarter net income were -31,030 K.
